Featured Publications
Performance characteristics of platelet autoantibody testing for the diagnosis of immune thrombocytopenia using strict clinical criteria
Gabe C, Sirotich E, Li N, Ivetic N, Nazy I, Smith J, Kelton J, Arnold D. Performance characteristics of platelet autoantibody testing for the diagnosis of immune thrombocytopenia using strict clinical criteria. British Journal Of Haematology 2021, 194: 439-443. PMID: 34109621, DOI: 10.1111/bjh.17566.Peer-Reviewed Original ResearchConceptsPlatelet autoantibody testingImmune thrombocytopeniaAutoantibody testingPlatelet autoantibodiesITP patientsDiagnosis of ITPCertain patient subsetsAnti-glycoprotein IIb/IIIaStrict clinical criteriaHigh pretest probabilityAntigen capture assayIIb/IIIaPatient subsetsClinical criteriaPretest probabilityTreatment responsePatientsHigher optical density valuesOptical density valuesThrombocytopeniaAutoantibodiesCapture assayDiagnosisSpecificityTesting
2022
SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry
Liew J, Gianfrancesco M, Harrison C, Izadi Z, Rush S, Lawson-Tovey S, Jacobsohn L, Ja C, Hyrich K, Gossec L, Strangfeld A, Carmona L, Schäfer M, Frãzao-Mateus E, Bulina I, Stafford F, Tufan A, Graver C, Yardımcı G, Zepa J, Al Emadi S, Cook C, Abutiban F, Dey D, Katigbak G, Kaufman L, Kowalski E, Martínez-Martínez M, Patel N, Reyes-Cordero G, Salido E, Smith E, Snow D, Sparks J, Wise L, Bhana S, Gore-Massy M, Grainger R, Hausmann J, Sirotich E, Sufka P, Wallace Z, Machado P, Robinson P, Yazdany J. SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry. RMD Open 2022, 8: e002187. PMID: 35387864, PMCID: PMC8987210, DOI: 10.1136/rmdopen-2021-002187.Peer-Reviewed Original ResearchConceptsB-cell depleting therapyBreakthrough infectionsRheumatic diseasesSARS-CoV-2Clinical characteristicsSARS-CoV-2 breakthrough infectionsPre-existing lung diseaseSARS-CoV-2 infectionBreakthrough COVID-19Cell-depleting therapyTwo-dose seriesTime of vaccinationSecond vaccine doseHigh-risk populationMessenger RNA vaccinesCOVID-19 symptomsSingle-dose vaccineCOVID-19Vaccination seriesSystemic glucocorticoidsVaccine doseVaccine effectivenessSecond doseVaccinated individualsLung disease
2021
Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry
Sparks J, Wallace Z, Seet A, Gianfrancesco M, Izadi Z, Hyrich K, Strangfeld A, Gossec L, Carmona L, Mateus E, Lawson-Tovey S, Trupin L, Rush S, Katz P, Schmajuk G, Jacobsohn L, Wise L, Gilbert E, Duarte-García A, Valenzuela-Almada M, Pons-Estel G, Isnardi C, Berbotto G, Hsu T, D’Silva K, Patel N, Kearsley-Fleet L, Schäfer M, Ribeiro S, Al Emadi S, Tidblad L, Scirè C, Raffeiner B, Thomas T, Flipo R, Avouac J, Seror R, Bernardes M, Cunha M, Hasseli R, Schulze-Koops H, Müller-Ladner U, Specker C, de Souza V, da Mota L, Gomides A, Dieudé P, Nikiphorou E, Kronzer V, Singh N, Ugarte-Gil M, Wallace B, Akpabio A, Thomas R, Bhana S, Costello W, Grainger R, Hausmann J, Liew J, Sirotich E, Sufka P, Robinson P, Machado P, Yazdany J, Dahou B, Quintana R, Gómez G, Roberts K, Baez R, Coello V, Salinas M, Maldonado F, Reyes A, Alle G, Tanten R, Ficco H, Nieto R, Gobbi C, Tissera Y, Pisoni C, Paula A, Albiero J, Schmid M, Cosatti M, Gamba M, Leandro C, Cusa M, German N, Bellomio V, Takashima L, Pera M, Cogo K, Elkin M, Medina M, Savio V, Tessel I, Alamino R, Werner M, Ornella S, Casalla L, de la Vega M, Severina M, García M, Lucero L, Romeo C, Moyano S, Barbich T, Bertoli A, Baños A, Petruzzelli S, Matellan C, Conti S, Lazaro M, Gil G, Risueño F, Quaglia M, Scafati J, Cuchiaro N, Rebak J, Pineda S, Calvo M, Picco E, Yanzi J, Maid P, Guaglianone D, Morbiducci J, Porta S, Herscovich N, Zamora J, Kisluk B, Menescardi M, Gallo R, Martire M, Maldini C, Goizueta C, de Fernandez S, Argentina C, Subils G, Rath E, Piette Y, Devinck M, Maeyaert B, Ribeiro F, Ribeiro S, Pinheiro M, Ibáñez S, Chassin-Trubert A, Dong L, Cajas L, Barešić M, Anić B, Čulo M, Pavelić T, Stranski K, Karanovic B, Vencovsky J, Píchová M, Filkova M, Hamoud H, Vassilopoulos D, Melgar G, So H, Király M, Vojdanian, Balbir-Gurman A, Abutiban F, Zepa J, Bulina I, Bukauskiene L, Zazueta-Montiel B, Castillo-Ortiz A, Zamora-Tehozol E, Vega-Morales D, Rosete D, Martín-Nares E, Rodriguez-Reyna T, Gabayet M, Alpízar-Rodríguez D, Irazoque F, Jimenez X, Bon L, Zijlstra T, Hoekstra M, Al-Adhoubi N, Salim B, Giraldo E, Salinas A, Ugarte-Gil M, Nowakowski J, Al-Emadi S, Conway R, Flood R, McCarthy G, Felea I, Filipescu I, Rednic S, Groseanu L, Tamas M, Mlynarikova V, Skamlova M, Zlnay M, Mičeková D, Capova L, Macejova Z, Šteňová E, Raffayova H, Belakova G, Strakova E, Senčarová M, Sabová A, Spisakova D, Oetterová M, Lukacova O, Bakosova M, Hocevar A, de la Torre-Rubio N, Sancho J, Coro M, Garcia J, Martin M, Campos J, Puerta J, Yardımcı G, Akar S, Icacan O, ÇELİK S, Vasylets V, Yeoh S, Vandevelde C, Dunt S, Leeder J, Macphie E, Salerno R, Graver C, Williams K, O'Reilly S, Devine K, Tyler J, Warner E, Pilcher J, Patel S, Nikiphorou E, Chadwick L, Jones C, Harrison B, Thornton L, O'Kane D, Fusi L, Low A, Horton S, Jatwani S, Baig S, Bajwa H, Berglund V, Dahle A, Dorman W, Hargrove J, Hilton M, Lebedoff N, Leonard S, Morgan J, Pfeifer E, Skemp A, Wilson J, Wolff A, Cepeda E, Todd D, Hare D, Calabrese C, Adams C, Khosroshahi A, Kilian A, White D, Winter M, Fields T, Siegel C, Daver N, Harvey M, Kramer N, Lamore C, Hogarty S, Yeter K, Wise L, Siddique F, Ban B, Tanner T, Ruderman E, Davis W, Quinet R, Scopelitis E, Toribio K, Webb-Detiege T, Zakem J, Abbass K, Kepecs G, Miranda L, Guma M, Haikal A, Mody S, Mueller D, Jayatilleke A, Zell J, Bays A, Dao K, Fatemeh E, Parks D, Karp D, Quiceno G. Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. Annals Of The Rheumatic Diseases 2021, 80: 1137-1146. PMID: 34049860, PMCID: PMC8172266, DOI: 10.1136/annrheumdis-2021-220418.Peer-Reviewed Original ResearchConceptsDisease-modifying antirheumatic drugsCOVID-19 severitySynthetic disease-modifying antirheumatic drugsWorse COVID-19 severityRheumatoid arthritisBaseline useCOVID-19 severity outcomeTumor necrosis factor inhibitorsInterleukin-6 inhibitorsNecrosis factor inhibitorsPotential baseline confoundersCOVID-19 outcomesPhysician registryCOVID-19IL-6iAntirheumatic drugsClinical onsetBaseline confoundersFactor inhibitorsOrdinal logistic regressionDrug classesRituximabAbataceptTNFiHospitalisationAssociation of Race and Ethnicity With COVID‐19 Outcomes in Rheumatic Disease: Data From the COVID‐19 Global Rheumatology Alliance Physician Registry
Gianfrancesco M, Leykina L, Izadi Z, Taylor T, Sparks J, Harrison C, Trupin L, Rush S, Schmajuk G, Katz P, Jacobsohn L, Hsu T, D’Silva K, Serling‐Boyd N, Wallwork R, Todd D, Bhana S, Costello W, Grainger R, Hausmann J, Liew J, Sirotich E, Sufka P, Wallace Z, Machado P, Robinson P, Yazdany J, Alliance T. Association of Race and Ethnicity With COVID‐19 Outcomes in Rheumatic Disease: Data From the COVID‐19 Global Rheumatology Alliance Physician Registry. Arthritis & Rheumatology 2021, 73: 374-380. PMID: 33146001, PMCID: PMC8467766, DOI: 10.1002/art.41567.Peer-Reviewed Original ResearchConceptsRheumatic diseasesGeneral US populationRace/ethnicityVentilatory supportLatinx patientsOdds ratioUS populationCOVID-19Rheumatic disease activityRheumatic disease diagnosisOdds of hospitalizationAfrican American patientsAssociation of raceCOVID-19 outcomesPhysician registryCoronavirus disease 2019COVID-19 hospitalizationMultivariable regression modelsSignificant health disparitiesNeeds of patientsInequitable health outcomesDisease activityHospitalized patientsMedication useWhite patientsFactors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry
Strangfeld A, Schäfer M, Gianfrancesco M, Lawson-Tovey S, Liew J, Ljung L, Mateus E, Richez C, Santos M, Schmajuk G, Scirè C, Sirotich E, Sparks J, Sufka P, Thomas T, Trupin L, Wallace Z, Al-Adely S, Bachiller-Corral J, Bhana S, Cacoub P, Carmona L, Costello R, Costello W, Gossec L, Grainger R, Hachulla E, Hasseli R, Hausmann J, Hyrich K, Izadi Z, Jacobsohn L, Katz P, Kearsley-Fleet L, Robinson P, Yazdany J, Machado P, Dahou B, Pinheiro M, Ribeiro F, Chassin-Trubert A, Ibáñez S, Dong L, Cajas L, Hamoud H, Avouac J, Belin V, Borie R, Chazerain P, Chevalier X, Claudepierre P, Clavel G, Colette-Cedoz M, Combe B, Constant E, Costedoat-Chalumeau N, Desmurs M, Devauchelle-Pensec V, Devaux M, Dhote R, Dieudonné Y, Domont F, Duret P, Ebbo M, Ebstein E, Mahou S, Fautrel B, Felten R, Flipo R, Foltz V, Froissart A, Galland J, Gaud-Listrat V, Georgin-Lavialle S, Giraud-Morelet A, Quitrec J, Goupille P, Govindaraju-Audouard S, Grados F, Guillaume-Czitrom S, Hermet M, Hittinger-Roux A, Hudry C, Kone-Paut I, La Batide Alanore S, Lafforgue P, Lahalle S, Lambrecht I, Langlois V, Larbre J, Ledoult E, Leroux C, Liote F, Maria A, Marotte H, Mekinian A, Melki I, Messer L, Michel C, Morel G, Morel J, Paris-Havard M, Pertuiset E, Pham T, Renard M, Revuz S, Rivière S, Rousselin C, Roux C, Rouzaud D, Sellam J, Seror R, Servettaz A, Sobanski V, Sordet C, Spielmann L, Tieulié N, Tison A, Trijau S, Virone A, Warzocha U, Wendling D, Albach F, Aries P, Decker E, Hartmann U, Henes J, Hoyer B, Krause A, Krüger K, Lorenz H, Müller-Ladner U, Pfeil A, Regierer A, Richter J, Rihl M, Schmeiser T, Schulze-Koops H, Specker C, Voll R, Werner S, Melgar G, Vojdanian, Andreoli L, Bartoloni-Bocci E, Benucci M, Campanaro F, Caprioli M, Carboni D, Carrara G, Cipolletta E, Crotti C, Dallagiacoma G, Faggioli P, Foti R, Franceschini F, Fredi M, Guidelli G, Iannone F, Landolfi G, Lomater C, Nalli C, Parisi S, Quartuccio L, Raffeiner B, Reggia R, Riva M, Romeo N, Rotondo C, Silvagni E, Sinigaglia L, Tinazzi I, Zanetti A, Zanframundo G, Abutiban F, Alpízar-Rodríguez D, Rull-Gabayet M, Irazoque F, Jimenez X, Martín-Nares E, Castillo-Ortiz A, Rodriguez-Reyna T, Rosete D, Zamora-Tehozol E, Vega-Morales D, Zaueta-Montiel B, Al-Adhoubi N, Salim B, Giraldo E, Salinas A, Ugarte-Gil M, Almeida D, Bernardes M, Machado R, Rato M, Al-Emadi S, Conway R, Flood R, Alegre-Sancho J, Coro M, de la Torre-Rubio N, Esteban J, del Martin M, Puerta J, Back J, Dastmalchi M, Dupré B, Grenholm E, Hensvold A, Knight A, Akar S, Icacan O, Chadwick L, Devine K, Dunt S, Fusi L, Jones C, Macphie E, Nikiphorou E, O'Kane D, O'Reilly S, Patel S, Salerno R, Thornton L, Tyler J, Vandevelde C, Warner E, Yeoh S, Baig S, Bajwa H, Ban B, Berglund V, Calabrese C, D'Silva K, Dahle A, Dao K, Daver N, Davis W, Dorman W, Fatemeh E, Fields T, Hargrove J, Harvey M, Hilton M, Hsu T, Izadi Z, Jayatilleke A, Karp D, Kepecs G, Kramer N, Lamore C, Lebedoff N, Leonard S, Mody S, Morgan J, Pfeifer E, Quiceno G, Quinet R, Rosenstein E, Ruderman E, Scopelitis E, Serling-Boyd N, Siddique F, Skemp A, Sparks J, Todd D, Toribio K, Wallwork R, Webb-Detiege T, White D, Wilson J, Winter M, Wise L, Wolff A, Young K, Zakem J, Zell J, Zimmerman K. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Annals Of The Rheumatic Diseases 2021, 80: 930-942. PMID: 33504483, PMCID: PMC7843211, DOI: 10.1136/annrheumdis-2020-219498.Peer-Reviewed Original ResearchConceptsDisease-modifying anti-rheumatic drugsCOVID-19-related deathsHigh disease activityRheumatic diseasesDisease activityHigher oddsBiological disease-modifying anti-rheumatic drugsMultivariable logistic regression modelRegistry of adultsRheumatic disease diagnosisAnti-rheumatic drugsChronic lung diseaseDisease-specific factorsAdequate disease controlLogistic regression modelsGlucocorticoid dosageMethotrexate monotherapyPrimary outcomeSmoking statusMale sexLung diseaseCardiovascular diseaseIndependent factorsDisease categoriesDisease control
2020
Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry
Gianfrancesco M, Hyrich K, Al-Adely S, Carmona L, Danila M, Gossec L, Izadi Z, Jacobsohn L, Katz P, Lawson-Tovey S, Mateus E, Rush S, Schmajuk G, Simard J, Strangfeld A, Trupin L, Wysham K, Bhana S, Costello W, Grainger R, Hausmann J, Liew J, Sirotich E, Sufka P, Wallace Z, Yazdany J, Machado P, Robinson P. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Annals Of The Rheumatic Diseases 2020, 79: 859-866. PMID: 32471903, PMCID: PMC7299648, DOI: 10.1136/annrheumdis-2020-217871.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAnti-Inflammatory Agents, Non-SteroidalAntimalarialsAntirheumatic AgentsArthritis, PsoriaticArthritis, RheumatoidBetacoronavirusBiological ProductsCoronavirus InfectionsCOVID-19FemaleGlucocorticoidsHospitalizationHumansJanus Kinase InhibitorsLupus Erythematosus, SystemicMaleMiddle AgedMultivariate AnalysisPandemicsPneumonia, ViralPrednisoneProtective FactorsRegistriesRheumatic DiseasesRisk FactorsSARS-CoV-2Severity of Illness IndexSpondylarthropathiesTumor Necrosis Factor InhibitorsVasculitisYoung AdultConceptsDisease-modifying antirheumatic drugsRheumatic diseasesHospitalisation statusHigher oddsNon-steroidal anti-inflammatory drug useConventional disease-modifying antirheumatic drugsAnti-inflammatory drug useOdds of hospitalisationRheumatic disease diagnosisRheumatic disease medicationsMultivariable-adjusted modelsMultivariable logistic regressionJanus kinase inhibitorCOVID-19 outcomesCOVID-19Prednisone doseAntirheumatic drugsGlucocorticoid exposureInhibitor useAntimalarial useClinical factorsCase seriesSmoking statusReduced oddsDecreased oddsManagement of major bleeds in patients with immune thrombocytopenia
Mithoowani S, Cervi A, Shah N, Ejaz R, Sirotich E, Barty R, Li N, Nazy I, Arnold D. Management of major bleeds in patients with immune thrombocytopenia. Journal Of Thrombosis And Haemostasis 2020, 18: 1783-1790. PMID: 32219982, DOI: 10.1111/jth.14809.Peer-Reviewed Original ResearchConceptsMajor bleedsImmune thrombocytopeniaEmergency departmentITP patientsEvidence-based treatment strategiesIntravenous immune globulinRetrospective cohort studyPermanent neurological disabilityITP therapyMajor bleedingRecurrent bleedsHemodynamic instabilityMinor bleedingCohort studyED visitsGross hematuriaImmune globulinAcute treatmentNeurological disabilityArterial thrombosisPlatelet transfusionsSevere thrombocytopeniaSignificant morbidityMale sexRisk factors